Orthocell completes first US military surgical case
Orthocell (ASX:OCC) completed its first Remplir surgical case in the US DoD/VA network.
Todas as matérias desta categoria, das mais recentes às mais antigas.
Orthocell (ASX:OCC) completed its first Remplir surgical case in the US DoD/VA network.
Immuron (ASX:IMC) recorded a double-digit increase in global sales for the third quarter of fiscal year 2026.
Radiopharm Theranostics (ASX:RAD) announced the completion of enrolment for its US Phase 2b imaging trial of RAD 101.
Xenitra (ASX:XEN) announced the 100% acquisition of Hong Kong Fukang Trading.
PYC Therapeutics (ASX:PYC) advances its PYC-001 drug candidate to multiple-dose testing for blinding eye disease ADOA.
FDA granted Immutep (ASX:IMM) Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma.
Orthocell (ASX:OCC) secured approval to supply its Remplir nerve repair device to 221 DoD and Veterans Affairs hospitals.
Genetic Signatures (ASX:GSS) has signed a multi-year supply agreement with Denmark's Hvidovre Hospital.
Mesoblast (ASX:MSB) has acquired an exclusive worldwide licence for a chimeric antigen receptor technology platform.
AVITA Medical (ASX:AVH) unveiled interim data from its Cohealyx-I multi-centre study.
Ryman Healthcare (ASX:RYM) reported a 10% lift in Q4 sales, meeting FY26 guidance despite village closures.
Telix Pharmaceuticals (ASX:TLX) announced the launch of a US$550 million offering of senior unsecured convertible notes due 2031.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade